Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK1 | P04183 | 6/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | ALB | P02768 | 2/20 | 0.40 |
| ▸ | BLM | P54132 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29364921 | 0.85 | TK1 (0.45) | TK1ALDH1A1LMNAALBBLM | |
| SCHEMBL16830721 | 0.85 | TK1 (0.43) | TK1ALDH1A1NPSR1LMNAALB | |
| SCHEMBL4809531 | 0.84 | TK1 (0.44) | TK1ALDH1A1LMNAALBBLM | |
| SCHEMBL135210 | 0.84 | TK1 (0.44) | TK1ALDH1A1NPSR1LMNAALB | |
| SCHEMBL16187026 | 0.84 | TK1 (0.44) | TK1ALDH1A1NPSR1LMNAALB | |
| SCHEMBL4542149 | 0.83 | TK1 (0.43) | TK1ALDH1A1LMNAALBBLM | |
| SCHEMBL7537552 | 0.83 | TK1 (0.43) | TK1ALDH1A1LMNAALBBLM | |
| SCHEMBL5849101 | 0.83 | TK1 (0.43) | TK1ALDH1A1LMNAALBBLM | |
| SCHEMBL660497 | 0.83 | TK1 (0.45) | TK1ALDH1A1LMNAALBBLM | |
| SCHEMBL8438314 | 0.83 | TK1 (0.43) | TK1ALDH1A1LMNAALBBLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120070825-A1 | Novel Compounds and Derivatizations of DNAs and RNAs on the Nucleobases of Pyrimidines for Function, Structure and Therapeutics | SENA RESEARCH, INC. (US) | 2012-03-22 | — | — | US | claimed |
| WO-2010135564-A2 | NOVEL COMPOUNDS AND DERIVATIZATION OF DNAS AND RNAS ON THE NUCLEOBASES OF PYRIMIDINES FOR FUNCTION, STRUCTURE, AND THERAPEUTICS | SENA RESEARCH, INC. (US) | 2010-11-25 | — | — | WO | claimed |
| US-8809357-B2 | Compounds and derivatizations of DNAs and RNAs on the nucleobases of pyrimidines for function, structure and therapeutics | HUANG, ZHEN, DR. | 2014-08-19 | — | — | US | disclosed |
| US-20120070825-A1 | Novel Compounds and Derivatizations of DNAs and RNAs on the Nucleobases of Pyrimidines for Function, Structure and Therapeutics | SENA RESEARCH, INC. (US) | 2012-03-22 | — | — | US | disclosed |
| WO-2010135564-A2 | NOVEL COMPOUNDS AND DERIVATIZATION OF DNAS AND RNAS ON THE NUCLEOBASES OF PYRIMIDINES FOR FUNCTION, STRUCTURE, AND THERAPEUTICS | SENA RESEARCH, INC. (US) | 2010-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120070825-A1 | Novel Compounds and Derivatizations of DNAs and RNAs on the Nucleobases of Pyrimidines for Function, Structure and Therapeutics | NSUN2, RNMT, TRDMT1 | TK1 59/4885ALDH1A1 736/4885NPSR1 3034/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.